2. Metabolic Enzyme/Protease NF-κB Immunology/Inflammation Cell Cycle/DNA Damage Apoptosis
  3. Phosphodiesterase (PDE) Reactive Oxygen Species (ROS) DNA/RNA Synthesis Apoptosis
  4. TDP1-IN-5

TDP1-IN-5 is a tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitor with an IC50 of 2.2 μM. By targeting TDP1 both intracellularly and extracellularly, TDP1-IN-5 inhibits the NHEJ repair pathway, arrests the cell cycle at the G2/M phase, upregulates PIG3 to enhance ROS, and ultimately significantly potentiates ionizing radiation (IR)-induced DNA damage and apoptosis. TDP1-IN-5 can be used in the research of colorectal cancer.

For research use only. We do not sell to patients.

TDP1-IN-5

TDP1-IN-5 Chemical Structure

CAS No. : 3115524-78-9

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

TDP1-IN-5 Related Antibodies

Top Publications Citing Use of Products

View All Phosphodiesterase (PDE) Isoform Specific Products:

View All Isoforms
PDE1 PDE2 PDE3 PDE4 PDE5 PDE6 PDE7 PDE9 PDE10 PDE11 PDE12 PDE8 Autotaxin

View All DNA/RNA Synthesis Isoform Specific Products:

View All Isoforms
RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

TDP1-IN-5 is a tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitor with an IC50 of 2.2 μM. By targeting TDP1 both intracellularly and extracellularly, TDP1-IN-5 inhibits the NHEJ repair pathway, arrests the cell cycle at the G2/M phase, upregulates PIG3 to enhance ROS, and ultimately significantly potentiates ionizing radiation (IR)-induced DNA damage and apoptosis. TDP1-IN-5 can be used in the research of colorectal cancer[1].

In Vitro

TDP1-IN-5 (Compound A6) (0.025-0.1 μM) exhibits strong radiosensitizing activity in HCT116 cells, with 83% cell killing when combined with 2 GY IR at 0.1 μM, and shows synergistic activity with a CI value as low as 0.20[1].
TDP1-IN-5 (Compound A6) (5-25 μM; 1 h) targets cellular TDP1 in HCT116 cells, stabilizing TDP1-DNA covalent complexes in a dose-dependent manner, with enhanced stabilization when combined with ionizing radiation[1].
TDP1-IN-5 (Compound A6) (1.25-5.0 μM) suppresses NHEJ repair activity in HCT116 cells in vitro in a dose-dependent manner, reducing repair by up to 42% at 5.0 μM[1].
TDP1-IN-5 (Compound A6) (5 μM; 6 h) enhances ionizing radiation-induced DNA damage in HCT116 cells, increasing γH2AX foci to 4.2-fold when combined with 4 GY IR at 5 μM[1].
TDP1-IN-5 (Compound A6) (1.25-2.5 μM) upregulates PIG3 protein expression in HCT116 cells, both alone and in combination with 4 GY ionizing radiation[1].
TDP1-IN-5 (Compound A6) (10 μM) enhances ionizing radiation-induced ROS production in HCT116 cells at 10 μM, while not inducing ROS production on its own[1].
TDP1-IN-5 (Compound A6) (5-10 μM; 24 h) induces G2/M cell cycle arrest in HCT116 cells in a dose-dependent manner, with enhanced arrest when combined with 4 GY ionizing radiation[1].
TDP1-IN-5 (Compound A6) (5-10 μM; 24 h) induces apoptosis in HCT116 cells in a dose-dependent manner, and significantly enhances ionizing radiation-induced apoptosis, reaching a 43.8% apoptotic ratio when combined with 4 GY IR at 10 μM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

TDP1-IN-5 Related Antibodies

Immunofluorescence[1]

Cell Line: HCT116 human colorectal cancer cells
Concentration: 5 μM
Incubation Time: 6 h
Result: Increased γH2AX foci by 1.5-fold when used alone compared to untreated cells.
Increased γH2AX foci to 4.2-fold above untreated levels when combined with 4 GY ionizing radiation (IR).

Cell Cycle Analysis[1]

Cell Line: HCT116 human colorectal cancer cells
Concentration: 5 μM, 10 μM
Incubation Time: 24 h
Result: Increased the G2/M phase cell proportion from 27.9% (control) to 40.2% at 5 μM when used alone.
Increased the G2/M phase cell proportion from 27.9% (control) to 47.9% at 10 μM when used alone.
Increased the G2/M phase proportion from 40.4% (IR alone) to 53.1% at 5 μM when combined with 4 GY ionizing radiation (IR).
Increased the G2/M phase proportion from 40.4% (IR alone) to 59.0% at 10 μM when combined with 4 GY IR.

Apoptosis Analysis[1]

Cell Line: HCT116 human colorectal cancer cells
Concentration: 5 μM, 10 μM
Incubation Time: 24 h
Result: Increased the apoptotic ratio from 4.1% (control) to 8.3% at 5 μM when used alone.
Increased the apoptotic ratio from 4.1% (control) to 22.2% at 10 μM when used alone.
Increased the apoptotic ratio from 13.5% (IR alone) to 19.4% at 5 μM when combined with 4 GY ionizing radiation (IR).
Increased the apoptotic ratio from 13.5% (IR alone) to 43.8% at 10 μM when combined with 4 GY IR.
In Vivo

TDP1-IN-5 (Compound A6) (10 mg/kg; i.p.; daily; 14 days) acts as an effective radiosensitizer in vivo, reducing HCT116 xenograft tumor weight by 79% when combined with 1 GY IR administered every two days for 14 days[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude (male, 4-5 weeks old, 15-18 g, subcutaneous xenograft model)[1]
Dosage: 10 mg/kg
Administration: i.p.; daily; 14 days
Result: Slightly inhibited tumor growth alone.
Reduced tumor weight by 79% when combined with 1 GY IR.
Caused slight body weight loss relative to controls alone.
Showed no obvious body weight difference compared to IR alone group when combined with IR.
Exhibited protective effect on liver and spleen weight against IR-induced reduction.
Molecular Weight

603.75

Formula

C34H45N5O5
CAS No.
SMILES

CN(C)CCN1C(C2=CC(OC)=C(OCCCN3CCN(CCN(C)C)CC3)C=C2C4=C1C(C=C(OCO5)C5=C6)=C6C=C4)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

TDP1-IN-5 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

TDP1-IN-53115524-78-9Phosphodiesterase (PDE)Reactive Oxygen Species (ROS)DNA/RNA SynthesisApoptosisHCT116 cellsTyrosyl-DNA phosphodiesterase 1 (TDP1)apoptosisG2/M cell cycle arrestNHEJ repair activityROS productionγH2AX fociSgTDP1-HCT116 cellscolorectal cancerPIG3Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
TDP1-IN-5
Cat. No.:
HY-183334
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.